Flyrcado is a diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Be Flyrcado Forward
Join cardiovascular experts across the U.S. preparing to expand access to cardiac PET. Flyrcado Forward, GE HealthCare’s program of peer-to-peer education and training for cardiac PET imaging centers, is here to help.
Join us at SNMMI for a Breakfast Symposium
Advancing cardiac PET accessibility: Implementing shared cardiac PET services with FlyrcadoTM (flurpiridaz F 18) injection
Sunday, June 22 | 6:45 – 7:45 a.m. Ballroom R06-07, Level 2, New Orleans Convention Center
During this interactive session you will:
Featured Speakers
Mouaz Al-Mallah, MD Houston Methodist
James Case, PhD Cardiovascular Imaging Technologies
About the session: Implementing a shared Myocardial Perfusion Imaging (MPI) PET/CT program, healthcare institutions can position themselves at the forefront of advanced cardiac imaging while optimizing resource utilization. Previously, however, implementing a shared program was hindered by the availability of cardiac PET tracers requiring an onsite cyclotron or generator. The introduction of FlyrcadoTM (flurpiridaz F 18) injection now provides accessibility of a unit dose cardiac PET tracer supplied from a local CMO allowing healthcare institutions to consider implementing a shared cardiac PET program without a large upfront financial commitment. This session will provide an overview of the practical considerations and clinical value of implementing a shared cardiac PET/CT MPI program with Flyrcado.
THE FIRST
NEW
F 18 MPI radiotracer in
OVER 20 YEARS
Gain greater diagnostic certainty in CAD
Flyrcado delivers precision in imaging1 and superior diagnostic accuracy over SPECT—even for challenging-to-image patients.2,3
Results from two large clinical trials demonstrate the superior sensitivity and non-inferior specificity of Flyrcado versus single-photon emission computed tomography (SPECT) MPI imaging in detecting coronary artery disease (CAD).
Enhance operational flexibility in cardiac PET
With on-demand unit doses delivered up to 5 days a week and a 109-minute half-life,1,2,4,5 Flyrcado enables operational flexibility for exercise stress testing and re-imaging due to technical difficulties, when needed, without re-dosing.2,4
Precision meets flexibility with Flyrcado
Versatile protocols due to longer half-life2,4,5
Superior image quality compared to SPECT1,2
Shorter positron range yields excellent resolution1
Support pharmacologic & exercise stress2
Convenience of unit dose delivered from local pharmacy1,6
Flyrcado brings cardiac PET to imaging centers in a broader range of sizes and locations4,5,7
Be Flyrcado Forward
At the 2025 SNMMI Annual Meeting, nuclear medicine leaders are coming together to explore the future
of nuclear medicine and molecular imaging.
We are excited to showcase Flyrcado at SNMMI 2025. Join your peers in the effort to expand access to cardiac PET imaging with the support of Flyrcado Forward. Sign up today for education and training opportunities with leading investigators and clinicians as you prepare to bring Flyrcado to your site of care.
Additional Support
Sign up for updates and resources to be Flyrcado Forward
References
IMPORTANT SAFETY INFORMATION
Indications and Usage
FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Contraindications
None
Warnings and Precautions
Adverse Reactions
To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at [email protected] or FDA at 800-FDA-1088 or www.fda.gov/medwatch
Please see the full Prescribing Information for additional important safety information.
GE HealthCare | Privacy Policy | Terms of Use | Contact Us | Unsubscribe
500 W. Monroe Street | Chicago, IL 60661
© 2025 GE HealthCare
Flyrcado is a trademark of GE HealthCare.
GE is a trademark of General Electric Company used under trademark license.
April 2025 | JB11555US